Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|7|1|42-50

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.7, Iss.1, 2018-01, pp. : 42-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in Non-Small Cell Lung Cancer

By Francesco Di Costanzo  

Drugs, Vol. 68, Iss. 6, 2008-01 ,pp. : 737-746

Adis International

Access to resources Recommend Favorite

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

By Schellhaas Elisabeth   Loddenkemper Christoph   Schmittel Alexander   Buhr Heinz-J.   Pohlen Uwe  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 184-187

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab AVAiLs in non-small cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1593, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

The role of afatinib in the management of non-small cell lung carcinoma

By Yap Timothy A   Popat Sanjay  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 11, 2013-11 ,pp. : 1529-1539

Informa Healthcare

Access to resources Recommend Favorite

Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy

By  

Current Drug Targets, Vol. 16, Iss. 13, 2015-12 ,pp. : 1448-1463

Bentham Science Publishers

Access to resources Recommend Favorite